Advertisement

The AMCP Managed Care & Specialty Pharmacy Annual Meeting is taking place April 23-26, in Boston, Massachusetts. Here we provide live coverage from the Specialty Connect pre-meeting with a focus on hemophilia, general education sessions, and poster presentations.

AMCP Annual Meeting 2018

A Review of Medicare Part D Updates

The Centers for Medicare & Medicaid Services (CMS) is addressing significant coverage gap changes created by the recently-passed Bipartisan Budget Act of 2018, according...

Updates in Biosimilar Legislation and Regulation

To date, 41 states and Puerto Rico have laws for biosimilars. However, federal and state regulations on biosimilars are confusing, incomplete, and often discourage...

The Case for Motivational Interviewing

Motivational interviewing is a direct, patient-centered conversational method that elicits positive change by helping patients explore and resolve ambivalence. The goal is to increase...

Challenges, Goals, and Strategies for the Management of Depression

Major depressive disorder is a complex, chronic, and recurrent illness that can affect other medical conditions. It is projected that 16.2 million Americans live...

The Value of Using Pharmacogenetic Risk Scores in Routine Practice

Conducting genetic tests for variants of drug metabolizing enzyme (DME) is a potential option for personalizing medication prescribing, optimizing patient outcomes, and reducing healthcare...

Both Chronic and Acute Opioid Users Have Increased Healthcare Utilization

Between 2000 and 2015, deaths from opioid prescriptions more than quadrupled, and evidence of long-term efficacy of opioids for chronic pain is limited. Researchers...

Study Compares Cost of Apremilast Versus Biologics for Patients with Psoriasis

Researchers sought to assess real-world costs associated with the oral agent apremilast for the treatment of biologic-naïve and biologic-experienced patients with psoriasis compared with...

Orphan Drug Outlook and the Management of These Agents

The U.S. Food and Drug Administration (FDA) currently has about 200 pending orphan drug designation requests, according to experts at a session on the...

Substantial Costs Associated with Acute Bleeding Events in Hemophilia A

Information on costs related to the treatment of acute bleeding events in patients with hemophilia A is lacking, so researchers evaluated the healthcare resource...

Economic Burden is Higher for Patients with Type 2 Diabetes and Comorbidities

Patients with type 2 diabetes can experience comorbidities that lead to hospitalizations and impact the economic disease burden. Researchers sought to estimate incremental all-cause healthcare...

Lessons Learned in Value-Based Contracts

Interest in value-based contracts continues to grow, but the most of these arrangements are not publicly known. A survey of 11 pharmaceutical manufacturers and...

Gene Therapy Management in Europe Versus the United States

The United States and Europe face many similar challenges in the management of gene therapies, including high upfront costs and the logistics of getting...

Optimizing Payer and Manufacturer Communication

The legislative and regulatory environment governing proactive communication between manufacturers and payers continues to evolve, according to experts at the AMCP Annual Meeting. Insights and...

Marketplace Trends: Specialty Spending, Generics and Biosimilars, Medication Adherence, and More

Total spending on medicine in the United States was $435 billion in 2017, with a growth of only 1.4%. Specialty growth is outpacing traditional...

General Session: Innovation and Change in the Healthcare System

AMCP CEO Susan Cantrell, RPh, CAE, began the General Session by discussing the trends in healthcare: “We need to free up space in the...

A Look at the Specialty Pharmacy Pipeline

Specialty drugs are those that involve frequent dosing adjustments and intensive clinical monitoring, as well as intensive patient training and compliance assistance, limited distribution,...

Change on the Horizon for the Management of Oncology

Oncology care is undergoing seismic change, driven largely by three factors: value-based care, precision medicine, and digital health. “The ground is shifting right under...

A Program Example to Combat Opioid Misuse and Abuse

The United States comprises approximately 4.4% of the global population but consumes 80% of opioids worldwide, and the majority of misuse comes from legally...

A Look at Gene Therapies in Development

Gene therapy involves the administration of genetic material to modify or manipulate the expression of genes or alter the biological properties of living cells....

CAR-T, CRISPR, and More Updates in Cancer Care and How to Pay for Them

Cancer remains a leading cause of morbidity and mortality in the United States, and the cost of cancer care is projected to reach $156...

Treatment Adherence Improves Paid Pharmacy Claims in Patients with Diabetes, Hypertension

Adherence to medications for diabetes, hypertension, and hyperlipidemia are triple-weighted metrics that can significantly impact Centers for Medicare & Medicaid Services’ Medicare Advantage Plan...

Past, Present, and Future of Hemophilia Care

Despite affecting only about 20,000 people, hemophilia ranks as one of the most expensive chronic diseases in the United States, with treatment costs as...

Hemophilia Care From the Payer Perspective

Hemophilia is a costly and complex disease, and while there has been “incredible growth” in treatment options—48 products are currently on the market—the increased...

Hemophilia Care: A Future for Gene Therapy?

The first gene therapy trial conducted in 1990 generated big headlines until it was reported in 1999 that a participant in one of the...

Panel Perspectives on Hemophilia Management

To conclude the Specialty Connect, a panel was convened to discuss various perspectives on the current climate of hemophilia care and projections for the...

Patient Treatment Preference for Biologic Asthma Agents

There are limited data on patient preferences for biologic agents for the treatment of asthma. Researchers assessed patient and physician perceptions on biologic agents...

Restrictions on Opioid Prescribing Result in Outcomes Aligned with CDC Guidelines

Access to pain medications has led to the current opioid epidemic. A risk management program reconsidered utilization management to limit inappropriate opioid use and...

Comparison of Healthcare Resource Utilization for Oral and Injectable Biologic Agents for Joint and...

Patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis may require biologic immunotherapy, which can be administered...
Advertisement